Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application.
The present work deals with the synthesis of a new series of thalidomide derivatives for therapeutic applications. These compounds were evaluated in vitro on a human endothelial cell line EA.hy926 for their antiproliferative potential and in vivo on an experimental animal multiple sclerosis model called EAE as angiogenesis inhibitors. The preliminary results obtained on EAE assays seem to validate that anti-angiogenesis compounds could be promising tools for the treatment of MS.
Contino-Pépin
Christiane
C
Université d'Avignon, Laboratoire de Chimie Bioorganique et des Systèmes Moléculaires Vectoriels, 33 rue Louis Pasteur, 84000 Avignon, France. christine.pepin@univ-avignon.fr
Parat
Audrey
A
Périno
Sandrine
S
Lenoir
Christine
C
Vidal
Michel
M
Galons
Hervé
H
Karlik
Stephen
S
Pucci
Bernard
B
D020533:Angiogenesis Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology*; D000818:Animals; D002460:Cell Line; D049109:Cell Proliferation; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D015195:Drug Design; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D042783:Endothelial Cells / Q000378:metabolism; D006801:Humans; D008956:Models, Chemical; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009389:Neovascularization, Pathologic; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology*
D020533:Angiogenesis Inhibitors; D013792:Thalidomide